TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tissue Repair Ltd ( (AU:TRP) ) just unveiled an announcement.
Tissue Repair Limited has made significant progress in its clinical trials and commercial expansion efforts. The company is advancing its Phase 3 trials for TR987® in the US and Australia, aiming for drug approval in the competitive wound care market. Additionally, Tissue Repair is pursuing a 510(k) device approval to expedite market entry. In parallel, TR Pro+® has achieved record sales growth, supported by new distribution agreements in Australia, New Zealand, and Thailand. The company’s financial position remains strong, with a cash balance of $12.3 million and increased revenue from TR Pro+® sales.
More about Tissue Repair Ltd
Tissue Repair Limited operates in the biotechnology industry, focusing on developing treatments for chronic wounds and aesthetic procedures. Its primary products include TR987® for chronic wound treatment and TR Pro+® for aesthetic and medical procedures. The company is actively working on expanding its market presence in the US, Australia, New Zealand, and Thailand, with plans to enter European markets.
Average Trading Volume: 71,371
Technical Sentiment Signal: Buy
Find detailed analytics on TRP stock on TipRanks’ Stock Analysis page.